Recent developments in biomarkers in Parkinson disease

Current Opinion in Neurology

Volumn 26, Issue 4, 2013, Pages 395-400

  Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

alpha synuclein; biomarker; genes; imaging; Parkinson disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; DJ 1 PROTEIN; GLUCOSYLCERAMIDASE; INTERLEUKIN DERIVATIVE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MESSENGER RNA; OREXIN; OSTEOPONTIN;

BRADYKINESIA; CLINICAL FEATURE; GENE MUTATION; HUMAN; LEWY BODY; MUSCLE RIGIDITY; NEUROFILAMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREMOR;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PARKINSON DISEASE;

EID: 84880759951     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283633741     Document Type: Review

References (58)

1. Shtilbans A, Henchcliffe C. Biomarkers in Parkinson's disease: an update. Curr Opin Neurol 2012; 25:460-465.
2. Mollenhauer B, Zhang J. Biochemical premotor biomarkers for Parkinson's disease. Mov Disord 2012; 27:644-650.
3. Chahine LM, Stern MB. Diagnostic markers for Parkinson's disease. Curr Opin Neurol 2011; 24:309-317.
4. Parnetti L, Castrioto A, Chiasserini D, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013; 9:131-140.
5. Nyhlen J, Constantinescu R, Zetterberg H. Problems associated with fluid biomarkers for Parkinson's disease. Biomark Med 2010; 4:671-681.
6. van Dijk KD, Teunissen CE, Drukarch B, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis 2010; 39:229-241.
7. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 2013; 20:16-34.
8. Schapira AH, Schrag A. Parkinson disease: Parkinson disease clinical subtypes and their implications. Nat Rev Neurol 2011; 7:247-248.
9. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Societysponsored revision of the Unified Parkinson's Disease Rating Scale (MDSUPDRS): scale presentation and clinimetric testing results.Mov Disord 2008; 23:2129-2170.
10. Olanow CW, Kieburtz K. Defining disease-modifying therapies for PD-a road map for moving forward. Mov Disord 2010; 25:1774-1779.
11. Chaudhuri KR, Healy DG, Schapira AH. Nonmotor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5:235-245. (Pubitemid 43238347)
12. Shannon KM, Keshavarzian A, Dodiya HB, et al. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 2012; 27:716-719.
13. Vogt T, Kramer K, Gartenschlaeger M, Schreckenberger M. Estimation of further disease progression of Parkinson's disease by dopamine transporter scan vs clinical rating. Parkinsonism Relat Disord 2011; 17:459-463.
14. Ravina B, Marek K, Eberly S, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord 2012; 27:1392-1397.
15. Berg D, Seppi K, Behnke S, et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 2011; 68:932-937.
16. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010; 133:3423-3433.
17. Zhan W, Kang GA, Glass GA, et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. Mov Disord 2012; 27:90-97.
18. Ulla M, Bonny JM, Ouchchane L, et al. Is r2 a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PLoS One 2013; 8:e57904.
19. Schapira AH. Mitochondrial diseases. Lancet 2012; 379:1825-1834.
20. Obeso JA, Rodriguez-Oroz MC, Goetz CG, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010; 16:653-661.
21. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011; 10:230-240.
22. Devic I, Hwang H, Edgar JS, et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011; 134 (Pt 7):e178.
23. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alphasynuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010; 75:1766-1772.
24. ParkMJ, Cheon SM, Bae HR, et al. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 2011; 7:215-222.
25. Sierks MR, Chatterjee G, McGraw C, et al. CSF levels of oligomeric alphasynuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) 2011; 3:1188-1196.
26. Foulds PG, Mitchell JD, Parker A, et al. Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 2011; 25:4127-4137.
27. Wang Y, Shi M, Chung KA, et al. Phosphorylated alpha-synuclein in Parkinson's disease. Sci Transl Med 2012; 4:121ra20.
28. Parnetti L, Chiasserini D, Bellomo G, et al. Cerebrospinal fluid Tau/alphasynuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 2011; 26:1428-1435.
29. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133 (Pt 3):713-726.
30. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69:570-580.
31. Shi M, Furay AR, Sossi V, et al. DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging 2012; 33:836-837.
32. Qiang JK, Wong YC, Siderowf A, et al. Plasma apolipoprotein A1 as a biomarker for Parkinson's disease. Ann Neurol 2013. 10.1002/ana.23872. [Epub ahead of print]
33. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol 2012; 69:380-384.
34. Prikrylova VH, Mares J, Hlustik P, et al. Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease. J Neural Transm 2012; 119:353-362.
35. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75:1055-1061.
36. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010; 81:1080-1086.
37. Bech S, Hjermind LE, Salvesen L, et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord 2012; 18:69-72.
38. Leverenz JB, Watson GS, Shofer J, et al. Cerebrospinal fluid biomarkers and cognitive performance in nondemented patients with Parkinson's disease. Parkinsonism Relat Disord 2011; 17:61-64.
39. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012; 11:697-707.
40. Chen-Plotkin AS, Hu WT, Siderowf A, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011; 69:655-663.
41. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med 2010; 4:701-712.
42. Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Curr Neurol Neurosci Rep 2012; 12:367-375.
43. Schwarzschild MA, Marek K, Eberly S, et al. Serum urate and probability of dopaminergic deficit in early 'Parkinson's disease'. Mov Disord 2011; 26: 1864-1868.
44. Bultron G, Kacena K, Pearson D, et al. The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis 2010; 33:167-173.
45. McNeill A, Duran R, Hughes DA, et al. A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry 2012; 83:853-854.
46. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146:37-52.
47. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 2012; 72:455-463.
48. Cleeter MW, Chau KY, Gluck C, et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int 2013; 62:1-7.
49. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 2010; 67:1464-1472.
50. Schapira AH, Gegg ME. Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci USA 2013; 110:3214-3215.
51. Lehnert S, Jesse S, Rist W, et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol 2012; 234:499-505.
52. Iranzo A, Lomena F, Stockner H, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. Lancet Neurol 2010; 9: 1070-1077.
53. Izawa MO, Miwa H, Kajimoto Y, Kondo T. Combination of transcranial sonography, olfactory testing, and MIBG myocardial scintigraphy as a diagnostic indicator for Parkinson's disease. Eur J Neurol 2012; 19:411-416.
54. Sierra M, Sanchez-Juan P, Martinez-Rodriguez MI, et al. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 2013; 80:621-626.
55. Hall S,Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012; 69:1445-1452.
56. Siderowf A, Jennings D, Eberly S, et al. Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord 2012; 27:406-412.
57. Schapira AH. Science, medicine, and the future: Parkinson's disease. BMJ 1999; 318:311-314. (Pubitemid 29195142)
58. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol 2010; 6:309-317.